WISDOM: An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations

Sponsor
Icahn School of Medicine at Mount Sinai (Other)
Overall Status
Completed
CT.gov ID
NCT01459744
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH), University of Colorado, Denver (Other), Mayo Clinic (Other), University of Pennsylvania (Other), Oregon Health and Science University (Other), Montefiore Medical Center (Other)
562
6
2
60
93.7
1.6

Study Details

Study Description

Brief Summary

An Implantable Cardioverter-Defibrillator (ICD) is a device implanted in a patient's chest to monitor the heart rhythm and deliver shocks to terminate potentially lethal arrhythmias when necessary. While ICDs reduce sudden cardiac death, patients with ICDs eventually die of heart failure or other diseases. As patients near the end of life, physiologic changes (intrinsic and extrinsic to the heart) may affect the cardiac conduction system, leading to more arrhythmias and increasing the frequency of shocks. Because ICD shocks can cause pain and anxiety and may not prolong a life of acceptable quality, it is appropriate to consider deactivating the shocking function of ICDs as patients' clinical status worsens and death is near. This will be a randomized controlled trial of a physician centered counseling and education intervention to improve clinician-patient communication about the management of ICDs.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Communication training for cardiologists.
  • Other: Control arm
N/A

Detailed Description

An Implantable Cardioverter-Defibrillator (ICD) is a device implanted in a patient's chest to monitor the heart rhythm and deliver shocks to terminate potentially lethal arrhythmias when necessary. While ICDs reduce sudden cardiac death, patients with these devices do eventually die, either of heart failure or other chronic diseases. As a patient's disease worsens, physiologic changes (intrinsic and extrinsic to the heart) may affect the cardiac conduction system, leading to more arrhythmias and increasing the frequency of shocks. Because ICD shocks can cause pain and anxiety and may not prolong a life of acceptable quality, it is appropriate to consider ICD deactivation as a patient's clinical status worsens and death is near. However, these conversations rarely occur. The investigators propose to conduct a randomized clinical trial of a physician-centered patient counseling and support intervention to improve communication between cardiologists and patients with ICDs. The goals of the study are to determine the effectiveness of the intervention to: 1) increase conversations about ICD deactivation, 2) increase the number of patients who have their devices deactivated, and 3) improve mental health outcomes for bereaved caregivers of deceased patients. The unit of randomization is the hospital, the intervention is aimed at cardiologists, and the unit of analysis is the patient. The investigators have created a network of six academic medical centers across the country. The intervention to be delivered consists of three parts. First, the PI will conduct a workshop on communication specific to ICD-deactivation with cardiologists at the intervention centers. Second, when enrolled patients are admitted to the hospital or seen in the outpatient setting, the cardiologist will receive two reminders (one via email, one in the patient chart) that the patient is appropriate for a conversation about ICD deactivation. Finally, cardiologists will receive aggregated feedback about the number of conversations they have conducted and data on patients' satisfaction with conversations every six months. Physicians at usual care hospitals receive a didactic lecture on advance care planning. All patients and surrogates will be interviewed at baseline and then assessed at regular intervals to determine the outcomes of: 1) the prevalence of conversations about ICD deactivation as reported by the patient/surrogate; and 2) the frequency with which patients have their devices deactivated. Caregivers will continue to be interviewed at regular intervals up to 6 months after the patient dies to determine the relationship of the intervention to caregiver mental health outcomes. Given the exponential increase in the number of patients with ICDs, this intervention has the potential to improve the quality of care for thousands of patients near the end of life and their families.

Study Design

Study Type:
Interventional
Actual Enrollment :
562 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)
Study Start Date :
Sep 1, 2011
Actual Primary Completion Date :
Sep 1, 2016
Actual Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Communication training for cardiologists

The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.

Behavioral: Communication training for cardiologists.
Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness. Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study. Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills.

Placebo Comparator: Control arm

Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.

Other: Control arm
Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.

Outcome Measures

Primary Outcome Measures

  1. Prevalence of Conversations about ICD Deactivation [after 1st clinical encounter after enrollment for intervention group]

    Whether deactivation discussion occurred difference between 1st and 3rd clinical encounters after enrollment

  2. Prevalence of Conversations about ICD Deactivation [3rd clinical encounter after enrollment for intervention group]

    Whether deactivation discussion occurred difference between 1st and 3rd clinical encounters after enrollment

  3. Prevalence of Conversations about ICD Deactivation [3 months after enrollment for control group]

    Whether deactivation discussion occurred difference between 3 and 9 months after enrollment

  4. Prevalence of Conversations about ICD Deactivation [9 months after enrollment for control group]

    Whether deactivation discussion occurred difference between 3 and 9 months after enrollment

Secondary Outcome Measures

  1. Prevalence of ICD Deactivation [After 1st encounter after enrollment for intervention group]

    Whether ICD deactivation occurred difference between 1st and 3rd clinical encounters after enrollment

  2. Prevalence of ICD Deactivation [After 3rd encounter after enrollment for intervention group]

    Whether ICD deactivation occurred difference between 1st and 3rd clinical encounters after enrollment

  3. Prevalence of ICD Deactivation [After 3 months after enrollment for control group]

    Whether ICD deactivation occurred difference between 3 and 9 months after enrollment

  4. Prevalence of ICD Deactivation [After 6 months after enrollment for control group]

    Whether ICD deactivation occurred difference between 3 and 9 months after enrollment

  5. Psychological Outcomes in Bereaved Caregivers [4 weeks after patient death]

  6. Psychological Outcomes in Bereaved Caregivers [6 months after patient death]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Clinicians:
  • At all sites, a core group of approximately 10 heart failure clinicians (physicians, nurses) care exclusively for patients with advanced heart failure in both inpatient and outpatient settings; all of these clinicians are eligible..
Patients:
  • Patient does not currently have a ventricular assist device

  • Age > 18

  • Fluent in English

  • Consistent and reliable access to a phone

For Inpatient:
  • Has had at least 1 other heart failure in the last year, OR

  • Meets all three of the following criteria at time of admission:

  1. BUN > 43

  2. SBP ≤ 115

  3. CR > 2.75 OR

  • Was on inotropes OR intravenous diuretics OR intravenous heart failure treatments in emergency department OR in outpatient setting prior to the current hospital admission

For Outpatient

  • Has had 2 or more heart failure related admissions in the last year OR

  • Has class IV heart failure in the outpatient setting OR

  • Has Class III heart failure in outpatient setting AND 1 heart failure related admission in the last year OR

  • Has Class III heart failure in outpatient setting AND 2 of the following 4 conditions:

  1. Age ≥ 70

  2. BUN ≥ 43

  3. Cr ≥ 2.75

  4. SBP≤115 OR

  • Is on inotropes (e.g., dobutamine, milrinone) OR intravenous diuretics OR intravenous heart failure treatments in emergency department OR in outpatient setting
Caregivers:
  • Age > 18

  • Fluent in English

  • Consistent and reliable access to a phone

Exclusion Criteria for patients:
  • Not having an ICD

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Colorado - Denver Denver Colorado United States 80045
2 Yale New-Haven Hospital New Haven Connecticut United States 06510
3 Mayo Medical Center Rochester Minnesota United States 55905
4 Montefiore Medical Center Bronx New York United States 10023
5 Icahn School of Medicine at Mount Sinai New York New York United States 10029
6 Hospital of the University of Pennsylvania Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • Icahn School of Medicine at Mount Sinai
  • National Heart, Lung, and Blood Institute (NHLBI)
  • University of Colorado, Denver
  • Mayo Clinic
  • University of Pennsylvania
  • Oregon Health and Science University
  • Montefiore Medical Center

Investigators

  • Principal Investigator: Nathan E. Goldstein, MD, Icahn School of Medicine at Mount Sinai

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01459744
Other Study ID Numbers:
  • GCO 09-0618
  • 1R01HL102084-01A1
First Posted:
Oct 26, 2011
Last Update Posted:
Oct 6, 2016
Last Verified:
Oct 1, 2016
Keywords provided by Icahn School of Medicine at Mount Sinai
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 6, 2016